膣および外陰部炎症性疾患治療の世界市場レポート 2025年

膣および外陰部炎症性疾患治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.39％で39億2,000万米ドルに成長します。予測期間の成長は、外陰部の健康に対する意識の高まり、非侵襲的治療に対する需要の高まり、慢性炎症性疾患の増加、ヘルスケアへのアクセスの拡大、ヘルスケア専門家の増加などが牽引すると予想されます。予測期間における主な動向としては、診断ツールの発展、診断における人工知能（AI）の統合、在宅ケアソリューションの台頭、膣ワクチンの開発、低侵襲手術技術の採用などが挙げられます。

糖尿病患者の増加は、膣および外陰部炎症性疾患治療市場の拡大を促進すると予想されます。糖尿病は、体内でインスリンを適切に生成または使用できないために血糖値が高くなる慢性疾患です。糖尿病の蔓延が拡大している背景には、座りがちなライフスタイル、食生活の乱れ、肥満の増加、遺伝的要因、高齢化などの要因があります。膣や外陰部の炎症性疾患の治療は、高血糖や免疫機能の低下によって頻繁に起こる感染症の再発を抑えるとともに、インスリン感受性を改善し、全体的な血糖管理を改善することで、糖尿病患者を助けます。例えば、2024年3月、英国のOffice for Health Improvement &Disparitiesは、2022年3月から2023年3月にかけて、推奨されるすべてのケアプロセスを受けた1型糖尿病患者が22％増加し、2型糖尿病患者は21％増加したと報告しました。さらに、37.9％がHbA1cの目標値を達成し、これは全国糖尿病監査（NDA）が記録した過去最高でした。その結果、糖尿病罹患率の増加が膣および外陰部炎症性疾患治療市場の成長を牽引しています。

膣および外陰部炎症性疾患治療市場の主なプレーヤーは、治療効果と患者の転帰を改善するために、膣シンバイオティクスなどの革新的な製品の開発に注力しています。膣シンバイオティクスは、膣マイクロバイオームをサポートし、バランスを維持し、感染を予防するために設計されたプロバイオティクスとプレバイオティクスの組み合わせです。例えば、2024年5月、米国のバイオテクノロジー企業であるシード・ヘルス社は、膣ケアを変革することを目的とした先駆的製品であるVS-01を発売しました。この世界初の製品は、マイクロバイオームのバランスをサポートすることで膣の健康を促進するよう科学的に処方されています。VS-01は、膣マイクロバイオームをターゲットとするプロバイオティクスの独自ブレンドを使用し、その自然な防御機能の維持をサポートします。先進のマイクロバイオーム科学を活用することで、この製品はバランスの乱れや不快感に対処し、膣の健康改善を目指す女性に包括的なソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膣および外陰部炎症性疾患治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の膣および外陰部炎症性疾患治療市場：成長率分析
• 世界の膣および外陰部炎症性疾患治療市場の実績：規模と成長, 2019-2024
• 世界の膣および外陰部炎症性疾患治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界膣および外陰部炎症性疾患治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膣および外陰部炎症性疾患治療市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膣の乾燥
• 膣の灼熱感
• 膣分泌物
• 性器のかゆみ
• 再発性尿路感染症
• 尿失禁
• その他の適応症
• 世界の膣および外陰部炎症性疾患治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• かゆみ止め薬
• コルチコステロイド軟膏
• かゆみ止めエモリエント
• 世界の膣および外陰部炎症性疾患治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 専門クリニック
• その他のエンドユーザー
• 世界の膣および外陰部炎症性疾患治療市場膣の乾燥の種類別分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 非ホルモン性保湿剤
• 潤滑剤および局所用薬剤
• 世界の膣および外陰部炎症性疾患治療市場膣灼熱感の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗炎症クリームとジェル
• 局所ステロイド
• 鎮痛薬
• 世界の膣および外陰部炎症性疾患治療市場膣分泌物の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗真菌治療
• 抗菌治療
• プロバイオティクスとプレバイオティクス
• 世界の膣および外陰部炎症性疾患治療市場性器のかゆみの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ヒスタミン薬
• 局所コルチコステロイド
• 抗真菌治療
• 世界の膣および外陰部炎症性疾患治療市場再発性尿路感染症（UTI）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• プロバイオティクス
• クランベリーベースのサプリメント
• 世界の膣および外陰部炎症性疾患治療市場尿失禁の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 行動療法
• 薬物（抗コリン薬、β3刺激薬）
• 外科的介入
• 世界の膣および外陰部炎症性疾患治療市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 硬化性苔癬
• 膣萎縮
• 骨盤底機能障害
• 外陰部前庭炎

第7章 地域別・国別分析

• 世界の膣および外陰部炎症性疾患治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膣および外陰部炎症性疾患治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膣および外陰部炎症性疾患治療市場：競合情勢
• 膣および外陰部炎症性疾患治療市場：企業プロファイル
  • Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Limited
• Sandoz International GmbH
• Hologic Inc.
• Ferring Pharmaceuticals
• Venus Concept Inc.
• Kyung Hee University Medical Center
• Duchesnay Inc.
• Evofem Biosciences Inc.
• SEID Lab
• Curive Healthcare Inc.
• Replens
• MC2 Therapeutics ApS
• FemiClear

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膣および外陰部炎症性疾患治療市場2029：新たな機会を提供する国
• 膣および外陰部炎症性疾患治療市場2029：新たな機会を提供するセグメント
• 膣および外陰部炎症性疾患治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vaginal and vulval inflammatory diseases encompass a group of conditions marked by inflammation of the vaginal and vulvar tissues, which may result in symptoms such as irritation, swelling, pain, redness, and sometimes infection. These conditions are commonly caused by bacterial, viral, or fungal infections, allergic reactions, skin disorders, or autoimmune diseases. Treatment generally involves addressing the root cause of the condition and managing symptoms through appropriate medical treatments and lifestyle changes.

The primary indications for treating vaginal and vulval inflammatory diseases include vaginal dryness, vaginal burning, vaginal discharge, genital itching, recurrent urinary tract infections, urinary incontinence, and other related issues. Vaginal dryness, often linked to reduced moisture in the vaginal area, is typically caused by hormonal changes, such as those seen during menopause. Treatment options include anti-itch medications, corticosteroid ointments, and emollients, and these are utilized by various end-users, including hospital pharmacies, specialty clinics, and other healthcare providers.

The vaginal and vulval inflammatory diseases treatment market research report is one of a series of new reports from The Business Research Company that provides vaginal and vulval inflammatory diseases treatment market statistics, including the vaginal and vulval inflammatory diseases treatment industry global market size, regional shares, competitors with the vaginal and vulval inflammatory diseases treatment market share, detailed vaginal and vulval inflammatory diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the vaginal and vulval inflammatory diseases treatment industry. This dark store market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vaginal and vulval inflammatory disease treatment market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.65%. The growth during the historic period can be attributed to the rising incidence of vaginal infections, growing awareness of women's health, improvements in healthcare infrastructure, an aging population, and increasing urbanization.

The vaginal and vulval inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.92 billion in 2029 at a compound annual growth rate (CAGR) of 6.39%. The growth in the forecast period is expected to be driven by greater awareness of vulvovaginal health, rising demand for non-invasive treatments, an increase in chronic inflammatory diseases, expanded access to healthcare, and a growing number of healthcare professionals. Key trends in the forecast period include advancements in diagnostic tools, the integration of artificial intelligence (AI) in diagnostics, the rise of home-based care solutions, the development of vaginal vaccines, and the adoption of minimally invasive surgical techniques.

The rise in diabetes cases is anticipated to fuel the expansion of the vaginal and vulval inflammatory disease treatment market. Diabetes is a chronic condition marked by high blood sugar levels due to the body's inability to produce or use insulin properly. The growing prevalence of diabetes can be linked to factors such as sedentary lifestyles, poor eating habits, increasing obesity, genetic factors, and an aging population. Treatments for vaginal and vulval inflammatory diseases help diabetes patients by reducing recurrent infections, which are frequent due to high blood sugar and compromised immune function, while also improving insulin sensitivity and overall blood sugar management. For example, in March 2024, the Office for Health Improvement & Disparities in the UK reported a 22% increase in individuals with type 1 diabetes receiving all recommended care processes from March 2022 to March 2023, and a 21% increase for type 2 diabetes. Additionally, 37.9% achieved target HbA1c levels, the highest ever recorded by the National Diabetes Audit (NDA). As a result, the growing incidence of diabetes is driving the growth of the vaginal and vulval inflammatory disease treatment market.

Key players in the vaginal and vulval inflammatory disease treatment market are focusing on the development of innovative products, such as vaginal synbiotics, to improve treatment effectiveness and patient outcomes. A vaginal synbiotic is a combination of probiotics and prebiotics designed to support the vaginal microbiome, maintain balance, and prevent infections. For example, in May 2024, Seed Health Inc., a biotechnology company based in the US, launched VS-01, a pioneering product intended to transform vaginal care. This first-of-its-kind product is scientifically formulated to promote vaginal health by supporting microbiome balance. VS-01 uses a proprietary blend of probiotics that target the vaginal microbiome, helping to preserve its natural defenses. By utilizing advanced microbiome science, this product addresses imbalances and discomfort, offering a comprehensive solution for women aiming to improve vaginal health.

In March 2023, GSK plc, a pharmaceutical company from the UK, entered into an exclusive partnership with SCYNEXIS Inc. to license and commercialize Brexafemme (ibrexafungerp). Through this collaboration, GSK plc seeks to expand its infectious disease portfolio by marketing Brexafemme for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC, as well as advancing its development for invasive candidiasis. This partnership addresses the growing demand for effective antifungal treatments. SCYNEXIS Inc., a US-based company, specializes in treatments for vulvovaginal candidiasis (VVC).

Major players in the vaginal and vulval inflammatory disease treatment market are Pfizer Incorporated, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hologic Inc., Ferring Pharmaceuticals, Venus Concept Inc., Kyung Hee University Medical Center, Duchesnay Inc., Evofem Biosciences Inc., SEID Lab, Curive Healthcare Inc., Replens, MC2 Therapeutics ApS, FemiClear.

North America was the largest region in the vaginal and vulval inflammatory disease treatment market in 2024. The regions covered in vulval inflammatory disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vaginal and vulval inflammatory disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vaginal and vulval inflammatory disease treatment market includes revenues earned by entities by providing services diagnostic services, pharmaceutical treatment services, and therapeutic procedures and related products such as antifungal creams, antibiotics, anti-inflammatory medications, hormonal therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vaginal And Vulval Inflammatory Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaginal and vulval inflammatory disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaginal and vulval inflammatory disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaginal and vulval inflammatory disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Vaginal Dryness; Vaginal Burning; Vaginal Discharge; Genital Itching; Recurrent Urinary Tract Infections; Urinary Incontinence; Other Indications
• 2) By Treatment: Anti-Itch Medications; Corticosteroid Ointments; Anti-Itch Emollients
• 3) By End User: Hospital Pharmacies; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Vaginal Dryness: Hormonal Therapy; Non-Hormonal Moisturizers; Lubricants and Topical Agents
• 2) By Vaginal Burning: Anti-inflammatory Creams and Gels; Topical Steroids; Pain Relief Medications
• 3) By Vaginal Discharge: Antifungal Treatments; Antibacterial Treatments; Probiotics and Prebiotics
• 4) By Genital Itching: Antihistamines; Topical Corticosteroids; Antifungal Treatments
• 5) By Recurrent Urinary Tract Infections (UTIs): Antibiotics; Probiotics; Cranberry-based Supplements
• 6) By Urinary Incontinence: Behavioral Therapy; Medications (Anticholinergics, Beta-3 Agonists); Surgical Interventions
• 7) By Other Indications: Lichen Sclerosus; Vaginal Atrophy; Pelvic Floor Dysfunction; Vulvar Vestibulitis
• Companies Mentioned: Pfizer Incorporated; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vaginal And Vulval Inflammatory Disease Treatment Market Characteristics

3. Vaginal And Vulval Inflammatory Disease Treatment Market Trends And Strategies

4. Vaginal And Vulval Inflammatory Disease Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vaginal And Vulval Inflammatory Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vaginal And Vulval Inflammatory Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vaginal And Vulval Inflammatory Disease Treatment Market Growth Rate Analysis
• 5.4. Global Vaginal And Vulval Inflammatory Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vaginal And Vulval Inflammatory Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vaginal And Vulval Inflammatory Disease Treatment Total Addressable Market (TAM)

6. Vaginal And Vulval Inflammatory Disease Treatment Market Segmentation

• 6.1. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaginal Dryness
• Vaginal Burning
• Vaginal Discharge
• Genital Itching
• Recurrent Urinary Tract Infections
• Urinary Incontinence
• Other Indications
• 6.2. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Itch Medications
• Corticosteroid Ointments
• Anti-Itch Emollients
• 6.3. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Specialty Clinics
• Other End-Users
• 6.4. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Vaginal Dryness, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Non-Hormonal Moisturizers
• Lubricants and Topical Agents
• 6.5. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Vaginal Burning, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-inflammatory Creams and Gels
• Topical Steroids
• Pain Relief Medications
• 6.6. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Vaginal Discharge, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifungal Treatments
• Antibacterial Treatments
• Probiotics and Prebiotics
• 6.7. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Genital Itching, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamines
• Topical Corticosteroids
• Antifungal Treatments
• 6.8. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Recurrent Urinary Tract Infections (UTIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Probiotics
• Cranberry-based Supplements
• 6.9. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Urinary Incontinence, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Behavioral Therapy
• Medications (Anticholinergics, Beta-3 Agonists)
• Surgical Interventions
• 6.10. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lichen Sclerosus
• Vaginal Atrophy
• Pelvic Floor Dysfunction
• Vulvar Vestibulitis

7. Vaginal And Vulval Inflammatory Disease Treatment Market Regional And Country Analysis

• 7.1. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market

• 8.1. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vaginal And Vulval Inflammatory Disease Treatment Market

• 9.1. China Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 9.2. China Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vaginal And Vulval Inflammatory Disease Treatment Market

• 10.1. India Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vaginal And Vulval Inflammatory Disease Treatment Market

• 11.1. Japan Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 11.2. Japan Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vaginal And Vulval Inflammatory Disease Treatment Market

• 12.1. Australia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market

• 13.1. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market

• 14.1. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 14.2. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market

• 15.1. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 15.2. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vaginal And Vulval Inflammatory Disease Treatment Market

• 16.1. UK Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vaginal And Vulval Inflammatory Disease Treatment Market

• 17.1. Germany Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vaginal And Vulval Inflammatory Disease Treatment Market

• 18.1. France Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vaginal And Vulval Inflammatory Disease Treatment Market

• 19.1. Italy Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vaginal And Vulval Inflammatory Disease Treatment Market

• 20.1. Spain Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market

• 21.1. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 21.2. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vaginal And Vulval Inflammatory Disease Treatment Market

• 22.1. Russia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vaginal And Vulval Inflammatory Disease Treatment Market

• 23.1. North America Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 23.2. North America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vaginal And Vulval Inflammatory Disease Treatment Market

• 24.1. USA Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 24.2. USA Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vaginal And Vulval Inflammatory Disease Treatment Market

• 25.1. Canada Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 25.2. Canada Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vaginal And Vulval Inflammatory Disease Treatment Market

• 26.1. South America Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 26.2. South America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market

• 27.1. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market

• 28.1. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 28.2. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vaginal And Vulval Inflammatory Disease Treatment Market

• 29.1. Africa Vaginal And Vulval Inflammatory Disease Treatment Market Overview
• 29.2. Africa Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vaginal And Vulval Inflammatory Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Vaginal And Vulval Inflammatory Disease Treatment Market Competitive Landscape
• 30.2. Vaginal And Vulval Inflammatory Disease Treatment Market Company Profiles
  • 30.2.1. Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Vaginal And Vulval Inflammatory Disease Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Eli Lilly and Company
• 31.3. Teva Pharmaceutical Industries Limited
• 31.4. Sandoz International GmbH
• 31.5. Hologic Inc.
• 31.6. Ferring Pharmaceuticals
• 31.7. Venus Concept Inc.
• 31.8. Kyung Hee University Medical Center
• 31.9. Duchesnay Inc.
• 31.10. Evofem Biosciences Inc.
• 31.11. SEID Lab
• 31.12. Curive Healthcare Inc.
• 31.13. Replens
• 31.14. MC2 Therapeutics ApS
• 31.15. FemiClear

32. Global Vaginal And Vulval Inflammatory Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vaginal And Vulval Inflammatory Disease Treatment Market

34. Recent Developments In The Vaginal And Vulval Inflammatory Disease Treatment Market

35. Vaginal And Vulval Inflammatory Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Vaginal And Vulval Inflammatory Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vaginal And Vulval Inflammatory Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vaginal And Vulval Inflammatory Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer